Prevalence and Factors Associated With Hyperglycemia Among Patients on Dolutegravir-Based Antiretroviral Therapy: A
Charles Nkubi Bagenda1,2, Carol Nantongo2,3, Michael Junior Mugisa1,4
1Department of Medical Laboratory Science, Faculty of Medicine, Mbarara University of Science and Technology, Mbarara City, Uganda.
Abstract:
BackgroundThe use of dolutegravir (DTG)-based antiretroviral therapy (ART) has been associated with the development of hyperglycemia. This study determined the prevalence and factors associated with hyperglycemia among people living with HIV (PLWH) on DTG-based ART in Uganda.MethodsWe conducted a cross-sectional study among 219 systematically recruited PLWH on DTG-based ART for ≥1 year at a Health Centre IV in Central Uganda. Data were collected using a structured questionnaire, anthropometric measurements, and laboratory investigations. Logistic regression was performed to identify factors associated with hyperglycemia.ResultsOut of 219 participants, 45 had fasting glucose ≥110 mg/dL, giving a hyperglycemia prevalence of 20.55% (95% confidence interval [CI]: 15.68%-26.45%). Overweight (aOR 8.11, 95% CI: 2.76-23.85, P < .001) and abnormal waist-to-hip ratio (aOR 4.36, 95% CI: 1.23-15.37, P = .022) were significantly associated with hyperglycemia.ConclusionsHyperglycemia is prevalent among PLWH on DTG-based ART and is potentially associated with overweight and abnormal waist-to-hip ratio.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes: Symptoms, Diagnosis, and Complications
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: Sulfonylureas
Therapeutic Drug Monitoring: Affecting Factors


